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 Abstract 
  Background/Aims:  Gene therapy involves delivery of exogenous DNA to provide a therapeutic 
protein. Ideally, a gene therapy vector should be non-toxic, non-immunogenic, easy to pro-
duce, and efficient in protecting and delivering DNA into target cells.   Methods:   Adeno-associ-
ated virus (AAV) offers these advantages and few, if any, disadvantages, and over 100 isolates 
exist. We previously showed that AAV-mediated gene therapy can be used to restore vision to 
patients with Leber’s congenital amaurosis, a disease of childhood blindness.   Results:   Here we 
show that novel recombinant AAV2/8 and AAV2/9 transduce kidney tubule cells with high ef-
ficiency both in vitro     in cell culture and in vivo     in mice. In addition, we adapted and modified a 
retrograde approach to allow for optimal transgene delivery to renal tubular cells that further 
minimizes the risk of an immunogenic reaction.   Conclusions:   We believe that recombinant 
AAV2, especially AAV2/8, gene delivery to renal tubule cells via a retrograde approach repre-
sents a viable method for gene therapy for a multitude of renal disorders ranging from autoso-
mal dominant polycystic kidney disease to acute kidney injury.    Copyright © 2011 S. Karger AG, Basel 
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 Introduction 
  Gene therapy involves delivery and targeting of exogenous DNA into cells to provide 
a therapeutic protein. Though no renal disease has yet successfully been treated in animals 
or patients using gene therapy, this modality holds great promise   [1]  . Ideally, a gene thera-
py vector should be non-toxic, non-immunogenic, easy to produce, and efficient in pro-
tecting and delivering DNA into the target cells. Exogenous DNA can be delivered with 
non-viral or viral vectors, each offering advantages and disadvantages. For example, al-
though non-viral vectors have low toxicity, their entrapment in endosomes with subse-
quent destruction of the cargo DNA, low efficiency, and transient expression currently 
limits their use   [2] .
    The use of viruses ensures highly efficient gene transfer to mammalian cells, as viruses 
have evolved specialized mechanisms for cell binding and intracellular delivery of DNA. 
Some viruses, however, such as adenoviruses, can evoke severe and even fatal immunogenic 
responses   [3]  . Retroviruses and lentiviruses have a tendency to integrate near transcription-
ally active genes resulting in leukemia-like syndromes in recipients   [4]  . On the other hand, 
adeno-associated virus (AAV) has many properties of an ideal gene therapy vector: 
    (1) AAV is non-toxic and AAV particles are endemic to human populations (up to 40% 
of adult humans in the Philadelphia area are seropositive), with no known clinical sequel-
ae   [5] . 
    (2) AAV particles have been selected by millions to billions of years of evolution for the 
delivery of DNA to cells, with features selected for endosomal entry, internal trafficking/
tropism for the cell nucleus, sizing to enter nuclear pores, payload delivery and degradation. 
  (3) The AAV ‘part list’ is complete, with the AAV capsid being composed of 60 subunits, 
comprising three closely related viral proteins (VP1, 90 kDa; VP2, 72 kDa, and VP3, 60 kDa), 
held together in a weakly bonded network   [6] . 
    (4) The receptor interaction is understood, with FGF and    v   5 being facilitators of host 
cell endocytosis, at least for AAV2   [7, 8] . 
  (5) The cell entry mechanism and path taken inside the cell are understood. For example, 
the mechanisms governing AAV2 entry (endosomal pathway) and internal trafficking are 
known   [9, 10] . 
    (6) AAV is engineerable by means of molecular biology, making it possible to optimize 
these particles for cell-specific delivery of genetic material, for minimizing immunogenicity, 
for tuning stability and particle lifetime, for efficient degradation, and for accurate delivery 
to the nucleus, for example. 
    (7) Nine natural serotypes and   1  100 additional isolates are available. AAV capsids can 
be exchanged using molecular engineering to generate novel recombinant AAVs, thus great-
ly increasing the chances of identifying an AAV that will optimally transduce a tissue of in-
terest, in our case kidney tubule cells. 
  Importantly, we showed that gene therapy with AAV can be used to restore vision to pa-
tients with Leber’s congenital amaurosis, a disease of childhood blindness   [11, 12] .
    The kidney is accessible to gene delivery by different routes, including via the renal ar-
tery, injection into the parenchyma, and retrograde injection via the ureter. Retrograde in-
jection is an attractive route for treating a variety of diseases and disorders affecting renal 
tubule cells, as these cells are readily accessible by retrograde ureteral injection. Equally im-
portant, retrograde ureteral injection further minimizes the potential for a toxic immuno-
logic reaction. We demonstrate here the feasibility of transducing renal tubule cells via the 
retrograde route and obtaining rapid transgene expression with recombinant AAV sero-
types, especially AAV2/8. 219
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  Materials  and  Methods 
 Cell  Culture 
  Low passage type I Madin-Darby canine kidney (MDCK) cells were obtained from 
Keith Mostov (University of California, San Francisco) and used between passages 3 and 10. 
  Western  Blot 
  Media from MDCK cells transduced with recombinant AAV encoding FLAG-tagged 
EGF-containing fibrillin-like extracellular matrix protein 1 (EFEMP1) were collected. Using 
antibody against the FLAG tag of EFEMP1, immunoprecipitation was performed and the 
protein solubilized in radio-immunoprecipitation assay buffer. Total protein content of the 
homogenate was determined using a bicinchoninic acid protein assay (Pierce Biotechnology, 
Rockford, Ill., USA) and EFEMP1 levels were determined using Western blot as described in 
the Results section. 
  A n i m a l s  
  Adult (4-week-old) C57BL/6 mice were used for all studies. All experiments were per-
formed in compliance with institutional regulations and were approved by the Institutional 
Animal Care and Use Committee. Under anesthesia, the kidney was surgically exposed and 
AAV virus was injected as described in the Results section. 
  H i s t o l o g y  
  Kidneys were removed following carbon dioxide-induced euthanasia and immediately 
fixed in 4% paraformaldehyde/PBS. They were cryoprotected in 30% sucrose/PBS overnight 
and frozen in optimal cutting temperature compound (Fisher Scientific, Pittsburgh, Pa., 
USA). For each kidney, serial sections were cut with a cryostat (Reichert Jung model 822; 
Leica Microsystems, Wetzlar, Germany) and counterstained with 4   ,6-diamidino-2-
phenylindole dihydrochloride (DAPI, Vectashield mounting medium; Vector Laboratories, 
Burlingame, Calif., USA). All were mounted and analyzed with a Leica DME microscope 
( Leica Microsystems ) equi pped wi th ep ifl uo rescen ce, and images w ere captured wi th a 
Hamamatsu digital camera and Openlab 2.2 image analysis software (Improvision, Boston, 
Mass., USA), as previously described   [13] .
    Production of AAV Vectors 
 Since the capsid protein of AAV is responsible for its tropism (and thus efficacy), a pseu-
dotyping strategy was used enabling the packaging of an AAV genome into the capsid of 
another serotype   [13]  . For production of recombinant AAVs (e.g. of the AAV2 genome), the 
AAV2 genome was packaged into an AAV1, 2, 5, 6, 7, 8 or 9 capsid using a triple transfection 
method, as described previously  [13, 14] . Viruses were concentrated via a heparin column or 
with 3  !   CsCl banding on a density gradient   [15]  . Titers were determined by real-time poly-
merase chain reaction   [16]  . The vectors carried transgene cassettes under the control of a 
cytomegalovirus (CMV) promoter. 
  R e s u l t s  
  Efficient Transduction of Polarized Kidney Tubule Cells  
  To determine which AAV would best transduce renal tubular epithelial cells, MDCK 
strain I cells were cultured as confluent epithelial monolayers on Transwell filters and ex-
posed to a panel of AAVs. The AAV2 serotype had the best transduction efficiency in this 220
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  Fig. 1.    a   Efficient transduction of polarized MDCK strain I cells is seen with AAV2/5.EFEMP1-FLAG. 
MDCK strain I cells were cultured as confluent epithelial monolayers on Transwell-Clear membranes and 
were exposed to AAV2/5 carrying WT FLAG-tagged EFEMP1: AAV2/5.EFEMP1-WT. Directional (apical; 
ap.) secretion of EFEMP1-WT was observed through immunoprecipitation of basal (bas.) and apical me-
dia.   b   Apical secretion persisted through 72 h after infection (the latest time point evaluated). Apical = 
Gray; basal = black bar.  c  Retrograde intra-ureter injection targeting renal tubule cells. Four-week-old WT 
mice were anesthetized and a 2-cm flank incision was made to expose the left kidney. The ureter was 
clamped below the renal pelvis to prevent the solution containing AAV from flowing in the opposite di-
rection of the kidney. Using a 30-gauge glass needle pipette and a microinjection apparatus, 50     l of PBS 
containing 1  !  10 9  genome copies of recombinant AAV2 virus were injected into the pelvis of the kidney. 
The viral medium contained a colored dye to help visualize the injection. After 5 min, the ureter clamp 
was released to allow urine flow to resume and to prevent obstruction of the kidney.   d–f   Reporter  gene 
expression in the kidney after in vivo     administration of novel AA Vs carrying CMV .Luciferase (  d )  or
CMV.EGFP (  e ,   f ).   d   Non-invasive imaging of luciferase bioluminescence using the Xenogen IVIS system 
2 weeks after injection of AAV2/9.CMV.Luciferase to the left ureter.   e   EGFP fluorescence in kidneys dis-
sected from representative animals 3 weeks after delivery of the designated AAV to the ureter. Scale bars 
( d–f  ) show intensity of transgene expression, with the red color indicating the highest levels.   f   Histologi-
cal studies reveal high levels of EGFP in renal tubular epithelial cells in the medulla and in the cortex (not 
shown) after retro-ureteral delivery of AAV.EGFP, but not in the contralateral untreated kidney. Dashed 
lines on the left side of the panel delineate the kidney and ureter. Arrows indicate strongly positive EGFP-
expressing tubules (inset  ! 120), while diffuse lower level EGFP expression is also seen. Nuclei are stained 
with DAPI (blue). 221
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system, and recombinant AAV2-based viruses (AAV2/2, 2/1, 2/5, 2/6, 2/7, 2/8 and 2/9) were 
further studied. For example, MDCK strain I cells growing as confluent monolayers on 
Transwell filters were exposed to recombinant AAV2/5 virus encoding wild-type (WT) 
FLAG-tagged EFEMP1: AAV2/5.EFEMP1-WT. Directional secretion of EFEMP1-WT was 
observed through immunoprecipitation of basal and apical media (  fig. 1  a). Apical secretion 
persisted through 72 h after infection (the latest time point evaluated;  fig. 1 b). As anticipated, 
EGFP (enhanced green fluorescent protein), delivered by transduction of additional aliquots 
of cells via AAV2/5.EGFP, was not observed in the media as EGFP, an intracellular protein, 
and is not secreted (data not shown). 
    Recombinant AAV Serotypes Delivering Reporters by Retrograde Injection  
  AAV-mediated gene transfer was then tested in vivo     by delivering 10  9   genome copies of 
the candidate AAV2 serotypes carrying CMV.EGFP or CMV.Luciferase via retrograde injec-
tion into the kidneys of WT mice. Retrograde injection involved a 2-cm left lateral incision 
under inhaled isoflurane anesthesia to expose the left kidney. The left ureter was isolated and 
clamped to prevent the vector solution containing AAV from flowing in the opposite direc-
tion of the kidney. PBS (50     l) containing 1   !   10 9   genome copies of AAV virus was injected 
into the ureter, just distal to the pelvis of the kidney, with a fine bore glass pipette attached 
to a nitrogen-powered microinjection/infusion apparatus. The viral medium also contained 
0.5     l of 0.25% fast green dye to help visualize the injection (  fig. 1  c).
    Two to 3 weeks after injection, animals were imaged for luciferase activity using a heat 
probe in sedated living mice (  fig. 1  d), or mice were euthanized, the kidneys harvested, cryo-
preserved, sectioned, and evaluated for EGFP expression (  fig. 1  e, f). AAV2/8 and AAV2/9 
serotypes resulted in high levels of reporter gene expression specific to the targeted kidney; 
lower levels of transgene expression were detected after injection of AAV2/6, AAV2/6.1.2, rh8 
(  fig. 1  e) and other recombinant AAV2 (not shown). 
    Histological evaluation revealed that EGFP was efficiently and specifically expressed in 
renal tubule cells in the kidney region exposed to virus (  fig. 1  f). There was no evidence of 
inflammation or an immune response relating to the presence of AAV capsid antigens or 
reporter proteins, and, by immunofluorescence, there was no evidence of hematological 
spread of the vector (data not shown). 
  Discussion 
  We report two principal findings. First, we show excellent transduction efficiency of re-
nal tubule cells using recombinant AAV2 serotypes, such as AAV2/8, in vitro     in cell culture 
and in vivo     in mice using two different reporters, luciferase and GFP. While a number of vi-
ruses, including lentivirus, adenovirus, and AAV serotypes 1–5 have been tested in vivo    in 
the kidney, none have resulted in as efficient or as stable transduction of tubule cells as we 
found with the recombinant virus AAV2/8   [2, 17–19]  . AAV-WT has been used to deliver 
transgenes to renal tubule epithelial cells  [20] ; however, recombinant AAV2/8 offers superior 
delivery. In addition, a problem with AAV-WT, which does not apply to recombinant AAVs, 
such as AAV2/8, is that transgene expression after transduction is delayed   [14] .
    Our second principal finding is that we can specifically and efficiently deliver AAV2/8 
to renal tubule epithelial cells via a modified retrograde approach. While retrograde injec-
tion of the ureter has been used to introduce reporter genes  [18] , it has not, to our knowledge, 
been used with AAV, and transduction efficiencies have been lower. An obvious advantage 
to a retrograde approach is that, if successful in animal trials of renal tubular disease, it could 
be scaled up to humans, and AAV2/8 encoding the appropriate cargo could be injected in a 222
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minimally invasive manner by urologists using ureteroscopy. Since many kidney diseases are 
bilaterally symmetrical, it is possible to perform controlled experiments targeting renal dis-
ease by using one kidney as the experimental kidney and the contralateral kidney as the con-
trol. Candidate diseases for treatment include autosomal dominant polycystic kidney disease 
and acute kidney injury. 
    If successful in humans, gene delivery using AAV2/8 injected in a retrograde manner 
would represent a novel treatment for the many disorders that manifest in renal tubule epi-
thelial cells. This is especially important given that there are currently no approved treat-
ments other than supportive care for many renal tubular disorders, including autosomal 
dominant polycystic kidney disease and acute kidney injury. 
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